Huang L, et al. - Researchers performed a retrospective analysis to compare the activity and tolerability of cisplatin and carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer (TNBC). Observations revealed no significant difference between the two regimens in terms of adverse events. It was noticed that both types of platinum salts and weekly paclitaxel were feasible therapies that achieved high pathological complete response (pCR) rates and tolerability in TNBC patients.